Latrepirdine is an orally-available drug, approved in Russia for use as a non-selective antihistamine, that has shown promise in the treatment of neurodegenerative diseases, including Alzheimer’s and Huntington’s disease. In addition to reported activity in preventing the onset and progression of disease by being neuroprotective, dimebolin appears to promote clinical improvement by increasing cognitive function. At the cellular level, dimebolin appears to have diverse effects, inhibiting the neurotoxic action of β-amyloid and blocking L-type calcium channels,5 inhibiting NMDA-type glutamate receptors, and preventing mitochondrial leakage.